류마티스관절염 환자에서 항 TNF 제제의 지속성 = Persistence with Anti-TNF Therapies in Patients with Rheumatoid Arthritis

참고문헌 (Reference)

1 조수경, "한국인 류마티스관절염 환자에서 항 TNF 제제의 지속성에 관한 연구" 대한류마티스학회 18 (18): 161-167, 2011

2 Gómez-Reino JJ, "on behalf of the BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0" Ann Rheum Dis In press 2011

3 Nixon R, "The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons" 46 : 1140-1147, 2007

4 Kievit W, "The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice" 66 : 1473-1478, 2007

5 Heiberg MS, "The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study" 59 : 234-240, 2008

6 Duclos M, "Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients" 33 : 2433-2438, 2006

7 Kievit W, "Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register" 50 : 196-203, 2011

8 Venkateshan SP, "Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis" 83 : 1-9, 2009

9 Zink A, "Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials" 54 : 3399-3407, 2006

10 Bartelds GM, "Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up" 305 : 1460-1468, 2011

11 Soliman MM, "British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register" 70 : 583-589, 2011

12 Carmona L, "BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER" 8 : 72-, 2006

13 Busquets N, "BIOBADASER 2.0 Study Group. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry" 50 : 1999-2004, 2011